Indeed, the application of a fourth mRNA vaccine dose induces not only increased titers of neutralizing antibodies, but also higher levels SARS-CoV-2-specific CD4+ and CD8+ T cell responses against the currently predominant VOC Omicron in patients with hematological malignancies [88]. This evidence concerns the gene CD4 and hematologic disorder.